| Trial Identifier: | D6070C00004 |
| Sponsor: | MedImmune, LLC |
| NCTID:: | NCT03381274 |
| Start Date: | May 2018 |
| Primary Completion Date: | May 2021 |
| Study Completion Date: | January 2024 |
| Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Korean Version | |
| Simplified Chinese (Taiwan) Version |
| Country | Location |
|---|---|
| KR | Seoul, KR, 05505 |
| KR | Seoul, KR, 03080 |
| KR | Seoul, KR, 06351 |
| TW | Taichung, TW, 40705 |
| US, CA | La Jolla, CA, US, 92093 |
| US, CA | San Francisco, CA, US, 94143 |
| US, CO | Aurora, CO, US, 80045 |
| US, CT | New Haven, CT, US, 06510 |
| US, FL | Gainesville, FL, US, 32608 |
| US, GA | Atlanta, GA, US, 30322 |
| US, IL | Chicago, IL, US, 60611 |
| US, MD | Baltimore, MD, US, 21224 |
| US, NY | New York, NY, US, 10032 |
| US, TX | Houston, TX, US, 77030 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company